Oxycodone / Acetaminophen · oral tablet
Analgesics
Approved uses
Pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
1 to 2 tablets of the 2.5 mg/325 mg strength every 6 hours as needed, at the lowest dose that gives adequate analgesia
Stronger than codeine and correspondingly harder to justify for surface pain such as an abrasion
Contraindications
- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to oxycodone, acetaminophen or any other component of the product, such as anaphylaxis
Tablets 2.5 mg/325 mg, 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg in bottles of 100; 5 mg/325 mg also in bottles of 500
Oxycodone is a full opioid agonist with relative selectivity for the mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect for analgesia with oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown.
Warnings & Precautions
- Addiction, abuse and misuse: PERCOCET exposes users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, and addiction can occur at recommended dosages. Assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions.
- Respiratory depression: serious, life-threatening, or fatal respiratory depression may occur with use of PERCOCET, especially during initiation or following a dosage increase. Proper dosing and titration of PERCOCET are essential to reduce the risk.
- Accidental ingestion: accidental ingestion of even one dose of PERCOCET, especially by children, can result in a fatal overdose of oxycodone.
- Hepatotoxicity: acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most cases of liver injury are associated with doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product. The risk is higher with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen. Instruct patients not to use more than one product that contains acetaminophen.
- Profound sedation, respiratory depression, coma, and death: these may result from concomitant use with benzodiazepines or other CNS depressants, including alcohol. Reserve concomitant prescribing for patients for whom alternative treatment options are inadequate, and prescribe the lowest effective dosages and minimum durations of concomitant use.
- Neonatal opioid withdrawal syndrome: use of PERCOCET for an extended period of time during pregnancy can result in withdrawal in the neonate, which may be life-threatening if not recognized and treated. Observe newborns for signs of neonatal opioid withdrawal syndrome. Advise pregnant women using opioids for an extended period of time of the risk and ensure that appropriate treatment will be available.
- Opioid analgesic REMS: FDA has required a Risk Evaluation and Mitigation Strategy (REMS) for opioid analgesics. Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to discuss safe use, serious risks, and proper storage and disposal with patients every time these medicines are prescribed.
- Increased oxycodone levels: a CYP3A4 inhibitor, such as erythromycin, ketoconazole or ritonavir, may increase oxycodone levels and prolong opioid adverse reactions, which may cause potentially fatal respiratory depression, particularly when an inhibitor is added after a stable dose is achieved. Stopping a CYP3A4 inducer, such as rifampin, carbamazepine or phenytoin, may also increase oxycodone levels. Evaluate patients at frequent intervals and consider dosage reduction until stable drug effects are achieved.
- Decreased opioid efficacy or withdrawal syndrome: adding a CYP3A4 inducer or stopping a CYP3A4 inhibitor could decrease oxycodone plasma concentrations, decrease opioid efficacy or, possibly, lead to a withdrawal syndrome in a patient who had developed physical dependence to oxycodone. Monitor patients closely at frequent intervals and consider increasing the opioid dosage if needed to maintain adequate analgesia or if symptoms of opioid withdrawal occur.
- Sleep-related breathing disorders: Opioids can cause central sleep apnea (CSA) and sleep-related hypoxemia, and opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the opioid dosage using best practices for opioid taper.
- Patient access to an opioid overdose reversal agent: Inform patients and caregivers about opioid overdose reversal agents (e.g., naloxone, nalmefene). Discuss the importance of having access to one, especially if the patient has risk factors for overdose (e.g., concomitant use of CNS depressants, a history of opioid use disorder, or prior opioid overdose) or if there are household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose.
- Opioid-induced hyperalgesia and allodynia: An opioid may paradoxically cause an increase in pain or in sensitivity to pain, and cases have been reported with both short-term and longer-term use. If opioid-induced hyperalgesia is suspected, carefully consider decreasing the dose of the current opioid or opioid rotation.
- Decreased respiratory drive including apnea: Patients with significant chronic obstructive pulmonary disease or cor pulmonale, substantially decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression are at increased risk of decreased respiratory drive including apnea, even at recommended dosages. Regularly evaluate these patients, particularly when initiating and titrating PERCOCET, or consider non-opioid analgesics.
- Respiratory depression in elderly or debilitated patients: life-threatening respiratory depression is more likely in elderly, cachectic, or debilitated patients because they may have altered pharmacokinetics or altered clearance. Regularly evaluate these patients, particularly when initiating and titrating PERCOCET and when PERCOCET is given concomitantly with other drugs that depress respiration, or consider non-opioid analgesics.
- Adrenal insufficiency: Cases have been reported with opioid use, more often after more than one month of use. If suspected, confirm the diagnosis with diagnostic testing as soon as possible; if diagnosed, treat with physiologic replacement doses of corticosteroids and wean the patient off the opioid.
- Severe hypotension: PERCOCET may cause severe hypotension including orthostatic hypotension and syncope in ambulatory patients. There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics). Regularly evaluate these patients for hypotension after initiating or titrating the dosage, and avoid use with circulatory shock.
- Serious skin reactions: Rarely, acetaminophen may cause acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Discontinue the drug at the first appearance of skin rash or any other sign of hypersensitivity.
- Hypersensitivity/anaphylaxis: There have been post-marketing reports of hypersensitivity and anaphylaxis with acetaminophen, with infrequent reports of life-threatening anaphylaxis. Instruct patients to discontinue PERCOCET immediately and seek medical care if symptoms occur. Do not prescribe PERCOCET for patients with acetaminophen allergy.
- Increased intracranial pressure: in patients who may be susceptible to the intracranial effects of carbon dioxide retention, such as those with increased intracranial pressure or brain tumors, PERCOCET may reduce respiratory drive, and the resultant retention can further increase intracranial pressure. Monitor such patients for sedation and respiratory depression, particularly when initiating therapy. Opioids may also obscure the clinical course of a head injury. Avoid PERCOCET in impaired consciousness or coma.
- Gastrointestinal complications: Opioids may obscure the diagnosis or clinical course in acute abdominal conditions. The oxycodone may cause spasm of the sphincter of Oddi, and opioids may cause increases in serum amylase; regularly evaluate patients with biliary tract disease, including acute pancreatitis, for worsening symptoms. Opioid-induced esophageal dysfunction (OIED) has been reported, and its risk may increase with opioid dose and/or duration; regularly evaluate patients for its signs and symptoms.
- Increased risk of seizures: The oxycodone in PERCOCET may increase the frequency of seizures in patients with seizure disorders, and may increase the risk of seizures in other clinical settings associated with seizures. Regularly evaluate patients with a history of seizure disorders for worsened seizure control.
- Withdrawal: Do not rapidly reduce or abruptly discontinue PERCOCET in a patient physically dependent on opioids; gradually taper the dosage. Rapid tapering of PERCOCET in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain. Avoid mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics, which may reduce the analgesic effect and/or precipitate withdrawal symptoms.
- Impaired mental or physical abilities: PERCOCET may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery. Warn patients not to drive or operate dangerous machinery unless they are tolerant to the effects of PERCOCET and know how they will react to the medication.
- Serotonin syndrome: Concomitant use of opioids with serotonergic drugs, such as SSRIs, SNRIs, tricyclic antidepressants, triptans, mirtazapine, trazodone, cyclobenzaprine, linezolid or intravenous methylene blue, has resulted in serotonin syndrome. If concomitant use is warranted, frequently evaluate the patient, particularly during treatment initiation and dose adjustment. Discontinue PERCOCET if serotonin syndrome is suspected.
- Serotonin syndrome or opioid toxicity: Concomitant use of opioids and MAOIs, such as phenelzine, tranylcypromine or linezolid, may manifest as serotonin syndrome or opioid toxicity (e.g., respiratory depression, coma). PERCOCET is not recommended for patients taking MAOIs or within 14 days of stopping such treatment. If urgent use of an opioid is necessary, use test doses and frequent titration of small doses while closely monitoring blood pressure and signs and symptoms of CNS and respiratory depression.
- Increased degree of respiratory depression: PERCOCET may enhance the neuromuscular blocking action of skeletal muscle relaxants, such as cyclobenzaprine and metaxalone, and produce an increased degree of respiratory depression. Monitor for respiratory depression that may be greater than otherwise expected, decrease the dosage of PERCOCET and/or the muscle relaxant as necessary, and consider recommending or prescribing an opioid overdose reversal agent.
- Urinary retention and severe constipation: The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Evaluate patients for signs of urinary retention or reduced gastric motility when PERCOCET is used with anticholinergic drugs.
- Decreased oxycodone clearance: Oxycodone clearance may decrease in patients with hepatic impairment or renal impairment. Initiate therapy with a lower than usual dosage of PERCOCET and titrate carefully, and regularly evaluate for adverse events such as respiratory depression, sedation, and hypotension.
- Reduced efficacy of diuretics: Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone. Evaluate patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.
- Interference with home blood glucose measurement: Acetaminophen may interfere with home blood glucose measurement systems; decreases of >20% in mean glucose values may be noted.
- Cross-reaction with urine drug assays: Depending on the sensitivity/specificity and the test methodology, the components of PERCOCET may cross-react with assays used in the preliminary detection of cocaine or marijuana in human urine. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result.
Common Side Effects
The most frequently observed non-serious adverse reactions include lightheadedness, dizziness, drowsiness or sedation, nausea, and vomiting.
Pregnancy: Prolonged use during pregnancy can cause neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated. It is not known whether PERCOCET can cause fetal harm, and it should not be given to a pregnant woman unless, in the judgment of the physician, the potential benefits outweigh the possible hazards. PERCOCET is not recommended during or immediately prior to labor, when other analgesic techniques are more appropriate.
Lactation: Available data from lactation studies indicate that oxycodone is present in breastmilk and that doses of less than 60 mg/day of the immediate-release formulation are unlikely to result in clinically relevant exposures in breastfed infants. Monitor infants exposed through breast milk for excess sedation and respiratory depression. Withdrawal symptoms can occur in breastfed infants when maternal opioid use or breastfeeding stops.
Safety and effectiveness of PERCOCET in pediatric patients have not been established.